The heat shock protein 90 inhibitor SNX-2112 inhibits B16 melanoma cell growth in vitro and in vivo

Oncology Reports

Volumn 27, Issue 6, 2012, Pages 1904-1910

  Liu, Kai Sheng ^a   Ding, Wei Chao ^a   Wang, Shao Xiang ^a   Liu, Zhong ^a   Xing, Guo Wen ^b   Wang, Ying ^a   Wang, Yi Fei ^a  

^a JINAN UNIVERSITY   (China)

^b BEIJING NORMAL UNIVERSITY   (China)

Author keywords

Apoptosis; B16 cells; Client protein; Heat shock protein 90 inhibitor; SNX 2112; Tumor growth

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; B RAF KINASE; EOSIN; GLYCOGEN SYNTHASE KINASE 3BETA; HEAT SHOCK PROTEIN 90; HEMATOXYLIN; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE B; SNX 2112; TANESPIMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G0 PHASE; CONTROLLED STUDY; DRUG POTENCY; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; IN VITRO STUDY; IN VIVO STUDY; MELANOMA B16; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; G1 PHASE CELL CYCLE CHECKPOINTS; GLYCOGEN SYNTHASE KINASE 3; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HSP90 HEAT-SHOCK PROTEINS; I-KAPPA B KINASE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84860783827     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1738     Document Type: Article

References (38)

1. Bishop SC, Burlison JA and Blagg BS: Hsp90: a novel target for the disruption of multiple signaling cascades. Curr Cancer Drug Targets 7: 369-388, 2007. (Pubitemid 46849241)
2. Chiosis G, Vilenchik M, Kim J and Solit D: Hsp90: the vulnerable chaperone. Drug Discov Today 9: 881-888, 2004. (Pubitemid 39314553)
3. Neckers L: Heat shock protein 90: the cancer chaperone. J Biosci 32: 517-530, 2007.
4. Zuehlke A and Johnson JL: Hsp90 and co-chaperones twist the functions of diverse client proteins. Biopolymers 93: 211-217, 2010.
5. Pearl LH and Prodromou C: Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 75: 271-294, 2006. (Pubitemid 44118034)
6. Burrows F, Zhang H and Kamal A: Hsp90 activation and cell cycle regulation. Cell Cycle 3: 1530-1536, 2004. (Pubitemid 40521406)
7. Zhang H and Burrows F: Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 82: 488-499, 2004. (Pubitemid 39149859)
8. Neckers L, Mimnaugh E and Schulte TW: Hsp90 as an anticancer target. Drug Resist Updat 2: 165-172, 1999.
9. Porter JR, Fritz CC and Depew KM: Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr Opin Chem Biol 14: 412-420, 2010.
10. Cysyk RL, Parker RJ, Barchi JJ Jr, Steeg PS, Hartman NR and Strong JM: Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications. Chem Res Toxicol 19: 376-381, 2006.
11. Taldone T, Sun W and Chiosis G: Discovery and development of heat shock protein 90 inhibitors. Bioorg Med Chem 17: 2225-2235, 2009.
12. Powers MV and Workman P: Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 13 (Suppl. 1): S125-S135, 2006. (Pubitemid 46219254)
13. Okawa Y, Hideshima T, Steed P, et al: SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 113: 846-855, 2009.
14. Bachleitner-Hofmann T, Sun MY, Chen CT, et al: Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET inhibition. Clin Cancer Res 17: 122-133, 2011.
15. Jin L, Xiao CL, Lu CH, et al: Transcriptomic and proteomic approach to studying SNX-2112-induced K562 cells apoptosis and anti-leukemia activity in K562-NOD/SCID mice. FEBS Lett 583: 1859-1866, 2009.
16. Wang SX, Ju HQ, Liu KS, et al: SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells. Biosci Biotechnol Biochem 75: 1540-1545, 2011.
17. Barta TE, Veal JM, Rice JW, et al: Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90. Bioorg Med Chem Lett 18: 3517-3521, 2008. (Pubitemid 351787571)
18. Pinon A, Limami Y, Micallef L, et al: A novel form of melanoma apoptosis resistance: melanogenesis up-regulation in apoptotic B16-F0 cells delays ursolic acid-triggered cell death. Exp Cell Res 317: 1669-1676, 2011.
19. Untch M, von Koch F, Kahlert S and Konecny G: Overview of epirubicin-based adjuvant therapy in breast cancer. Clin Breast Cancer 1 (Suppl 1): S41-S45, 2000.
20. Rakitina TV, Vasilevskaya IA and O'Dwyer PJ: Inhibition of G1/S transition potentiates oxaliplatin-induced cell death in colon cancer cell lines. Biochem Pharmacol 73: 1715-1726, 2007. (Pubitemid 46601405)
21. Georgakis GV, Li Y and Younes A: The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9. Br J Haematol 135: 68-71, 2006. (Pubitemid 44337664)
22. Theodoraki MA and Caplan AJ: Quality control and fate determination of Hsp90 client proteins. Biochim Biophys Acta 1823: 683-688 2011.
23. Massey AJ, Schoepfer J, Brough PA, et al: Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800. Mol Cancer Ther 9: 906-919, 2010.
24. Banerji U: Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 15: 9-14, 2009.
25. Ye Y, Wang H, Chu JH, et al: Atractylenolide II induces G1 cell-cycle arrest and apoptosis in B16 melanoma cells. J Ethnopharmacol 136: 279-282, 2011.
26. Samadi AK, Zhang X, Mukerji R, Donnelly AC, Blagg BS and Cohen MS: A novel C-terminal HSP90 inhibitor KU135 induces apoptosis and cell cycle arrest in melanoma cells. Cancer Lett 312: 158-167, 2011.
27. Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE and Gambacorti-Passerini C: BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 6: 751-759, 2008.
28. Panka DJ, Cho DC, Atkins MB and Mier JW: GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. J Biol Chem 283: 726-732, 2008.
29. Papp T, Niemetz A, Dosdahl N, Kumar K and Schiffmann D: Mutational analysis of Chk1, Chk2, Apaf1 and Rb1 in human malignant melanoma cell lines. Oncol Rep 17: 135-140, 2007.
30. Russo AE, Torrisi E, Bevelacqua Y, et al: Melanoma: molecular pathogenesis and emerging target therapies (review). Int J Oncol 34: 1481-1489, 2009.
31. Mehta PP, Kung PP, Yamazaki S, et al: A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells. Cancer Lett 300: 30-39, 2011.
32. Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002. (Pubitemid 37328931)
33. Jia W, Yu C, Rahmani M, et al: Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways. Blood 102: 1824-1832, 2003. (Pubitemid 37022579)
34. Park K, Choi K, Kim H, et al: Isoflavone-deprived soy peptide suppresses mammary tumorigenesis by inducing apoptosis. Exp Mol Med 41: 371-381, 2009.
35. Prasad S, Ravindran J and Aggarwal BB: NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem 336: 25-37, 2010.
36. Lochhead PA, Kinstrie R, Sibbet G, Rawjee T, Morrice N and Cleghon V: A chaperone-dependent GSK3beta transitional intermediate mediates activation-loop autophosphorylation. Mol Cell 24: 627-633, 2006. (Pubitemid 350284229)
37. Kurashina R, Ohyashiki JH, Kobayashi C, et al: Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via betacatenin/ TCF7L2 pathway in adult T cell leukemia cells. Cancer Lett 284: 62-70, 2009.
38. Beurel E and Jope RS: The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 79: 173-189, 2006. (Pubitemid 44331500)